Atomo NewsGet the app

Get the latest Science News and Discoveries

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC


Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Get the Android app

Or read this on Eureka Alert

Read more on:

Photo of NSCLC

NSCLC

Photo of pembrolizumab

pembrolizumab

Photo of primary endpoints

primary endpoints

Related news:

News photo

Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC

News photo

Adjuvant immunotherapy shows no survival benefit for NSCLC patients achieving pCR after neoadjuvant treatment

News photo

Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC) - EurekAlert!

« Earth Is A Sitting Duck If Sun Unleashes Superstorm, Scientists Say
Phase III TAISHAN-302 trial shows Tam-Peli significantly improves survival in relapsed small-cell lung cancer »